Sydney, March 4, 2026, 18:25 AEDT — The market has closed.
- Pro Medicus shares clawed back some ground, closing higher after tumbling sharply the previous day.
- The ASX dropped, weighed down by renewed Middle East tensions, rising oil, and more talk of rate hikes.
- Traders are tracking the RBA’s March decision, with PME’s dividend date also coming up late in the month.
Pro Medicus Ltd (PME.AX) shares picked up 1.7% on Wednesday, closing at A$116.19. The stock moved in a range from A$113.01 to A$118.28 during the session.
Australian stocks dropped once more, the S&P/ASX 200 slipping 1.9% as worries mounted over an extended Middle East conflict, pricier oil, and fresh inflation risks. Tony Sycamore at IG noted the GDP figures had a “decent kick,” but cautioned the central bank remains “laser-focused” on potential supply shocks from the turmoil. Abhijit Surya of Capital Economics described the data as a “mixed bag” and maintained his view that more tightening could be on the cards. ABC News
Pro Medicus slid 8.77% on Tuesday, making it one of the session’s weakest performers as the benchmark shed 1.34%. Life360 was hit even harder, tumbling 16.26%. Independent economist Saul Eslake called the bond rout a “direct response” to remarks from Reserve Bank of Australia governor Michele Bullock. According to Eslake, markets are “factoring in” increased tightening, with money markets pricing in roughly a 30% shot at a rate hike on March 17. ABC News
Director buying has drawn fresh attention to the stock. Co-founders Anthony Hall and Sam Hupert snapped up A$3.4 million in shares over four on-market trades, paying a weighted average of A$113.52, according to Market Index. The activity follows what Market Index called a sector de-rating linked to “AI disruption” worries and contract timing. Market Index
No new Pro Medicus updates turned up on the ASX market announcements for Wednesday or the session before, so investors chalked up the day’s price swings to bigger-picture news and shifting bets.
Pro Medicus, based in Richmond, makes medical imaging software such as the Visage 7 platform and radiology information systems, according to TradingView’s company profile.
Still, volatility hasn’t left the stage. Pro Medicus, which behaves much like a growth stock, is known for sharp moves—especially when oil prices surge or rate expectations shift quickly.
Timing throws another wrench in the works. Big hospital deals often land in clusters, and rollout timelines can shove revenue from one half to the next. Stocks that expect flawless delivery can take the hit.
Thursday brings another test for traders, who are looking for signs that buyers will step in after two volatile sessions and a choppy mix across sectors. Should the broader market continue to slip, PME could have trouble hanging onto its gains—even in the absence of fresh headlines from the company.
Looking past the upcoming session, one thing on the short-term calendar: Pro Medicus shareholders are set to receive their interim dividend on March 20, following the ex-dividend date of Feb. 26.
